Aspire Private Capital LLC cut its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 10.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 308 shares of the medical research company’s stock after selling 37 shares during the quarter. Aspire Private Capital LLC’s holdings in Amgen were worth $89,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Southland Equity Partners LLC boosted its holdings in shares of Amgen by 2.3% in the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock valued at $443,000 after purchasing an additional 34 shares in the last quarter. Acropolis Investment Management LLC raised its position in shares of Amgen by 3.5% during the fourth quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock worth $288,000 after purchasing an additional 34 shares during the period. Opal Wealth Advisors LLC lifted its stake in shares of Amgen by 1.9% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after buying an additional 34 shares in the last quarter. Marino Stram & Associates LLC boosted its stake in Amgen by 0.7% during the 4th quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock valued at $1,332,000 after purchasing an additional 34 shares during the last quarter. Finally, FORVIS Wealth Advisors LLC grew its holdings in Amgen by 1.4% during the fourth quarter. FORVIS Wealth Advisors LLC now owns 2,578 shares of the medical research company’s stock worth $743,000 after buying an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Amgen Stock Up 0.4 %
AMGN stock traded up $1.22 during mid-day trading on Tuesday, hitting $273.13. 359,777 shares of the company were exchanged, compared to its average volume of 2,817,588. The firm has a market cap of $146.50 billion, a P/E ratio of 21.77, a P/E/G ratio of 2.50 and a beta of 0.58. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The firm’s 50 day simple moving average is $276.45 and its 200 day simple moving average is $281.56. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65.
Amgen Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.30%. Amgen’s dividend payout ratio (DPR) is currently 72.06%.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on AMGN shares. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Royal Bank of Canada reiterated an “outperform” rating and set a $329.00 price objective on shares of Amgen in a research note on Wednesday, April 3rd. Raymond James initiated coverage on shares of Amgen in a research report on Thursday, March 28th. They issued a “market perform” rating on the stock. UBS Group cut their target price on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Finally, TD Cowen decreased their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Amgen has an average rating of “Moderate Buy” and a consensus price target of $296.95.
Read Our Latest Stock Analysis on Amgen
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Read More
- Five stocks we like better than Amgen
- The How and Why of Investing in Biotech Stocks
- Charles Schwab Fortifies its Uptrend on EPS Beat
- 10 Best Airline Stocks to Buy
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Most Volatile Stocks, What Investors Need to Know
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.